ARCA biopharma, Inc. Common Stock, also called ARCA biopharma, is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. Read More The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO. The listed name for ABIO is ARCA biopharma, Inc. Common Stock.